Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends

[1]  O. Howes,et al.  New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side-effect profile relative to established antipsychotics , 2021, Neuroscience & Biobehavioral Reviews.

[2]  S. Kaiser,et al.  Antipsychotics for negative and positive symptoms of schizophrenia: dose-response meta-analysis of randomized controlled acute phase trials , 2021, npj Schizophrenia.

[3]  A. Tanskanen,et al.  Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. , 2021, The lancet. Psychiatry.

[4]  A. Carvalho,et al.  Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review , 2021, World psychiatry : official journal of the World Psychiatric Association.

[5]  P. Falkai,et al.  EPA guidance on treatment of negative symptoms in schizophrenia , 2021, European Psychiatry.

[6]  John M. Davis,et al.  Short-acting intramuscular second-generation antipsychotic drugs for acutely agitated patients with schizophrenia spectrum disorders. A systematic review and network meta-analysis , 2021, Schizophrenia Research.

[7]  P. Falkai,et al.  Characteristics and definitions of ultra-treatment-resistant schizophrenia – A systematic review and meta-analysis , 2021, Schizophrenia Research.

[8]  M. Zeegers,et al.  Citation bias and other determinants of citation in biomedical research: findings from six citation networks. , 2020, Journal of clinical epidemiology.

[9]  Philipp Mayr,et al.  The journal coverage of Web of Science, Scopus and Dimensions: A comparative analysis , 2020, Scientometrics.

[10]  C. Correll,et al.  Safety of 80 antidepressants, antipsychotics, anti‐attention‐deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta‐review of 78 adverse effects , 2020, World psychiatry : official journal of the World Psychiatric Association.

[11]  Ludo Waltman,et al.  Large-scale comparison of bibliographic data sources: Scopus, Web of Science, Dimensions, Crossref, and Microsoft Academic , 2020, Quantitative Science Studies.

[12]  C. Correll,et al.  Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study , 2020, Schizophrenia Research.

[13]  T. Ikuta,et al.  Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis , 2020, Psychopharmacology.

[14]  Andrea Cipriani,et al.  Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis , 2020, The lancet. Psychiatry.

[15]  Andrea Cipriani,et al.  Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis , 2019, The Lancet.

[16]  M. Egger,et al.  Synthesizing existing evidence to design future trials: survey of methodologists from European institutions , 2019, Trials.

[17]  Shinichi Nakagawa,et al.  Research Weaving: Visualizing the Future of Research Synthesis. , 2018, Trends in ecology & evolution.

[18]  C. Correll,et al.  Tardive dyskinesia risk with first‐ and second‐generation antipsychotics in comparative randomized controlled trials: a meta‐analysis , 2018, World psychiatry : official journal of the World Psychiatric Association.

[19]  O. Howes,et al.  Antipsychotic drugs: challenges and future directions , 2018, World psychiatry : official journal of the World Psychiatric Association.

[20]  B. Penninx,et al.  Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications , 2018, Dialogues in clinical neuroscience.

[21]  A. Vernon,et al.  Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability , 2018, Neuroscience & Biobehavioral Reviews.

[22]  P. McGuire,et al.  Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. , 2017, The American journal of psychiatry.

[23]  Massimo Aria,et al.  bibliometrix: An R-tool for comprehensive science mapping analysis , 2017, J. Informetrics.

[24]  Andrew S. Pullin,et al.  Evidence maps and evidence gaps: evidence review mapping as a method for collating and appraising evidence reviews to inform research and policy , 2017, Environmental Evidence.

[25]  A. Tanskanen,et al.  Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia , 2017, JAMA psychiatry.

[26]  H. Möller,et al.  Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. , 2017, The American journal of psychiatry.

[27]  C. Correll,et al.  Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta‐analysis and meta‐regression analysis , 2017, World psychiatry : official journal of the World Psychiatric Association.

[28]  D. Goldsmith,et al.  A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression , 2016, Molecular Psychiatry.

[29]  Sascha Friesike,et al.  Opening Science: The Evolving Guide on How the Internet is Changing Research, Collaboration and Scholarly Publishing , 2016 .

[30]  A. Vita,et al.  Schizophrenia , 2016, The Lancet.

[31]  John P A Ioannidis,et al.  The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and Meta-analyses. , 2016, The Milbank quarterly.

[32]  M. Olfson,et al.  Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis. , 2016, JAMA psychiatry.

[33]  Jian Wang,et al.  Bias Against Novelty in Science: A Cautionary Tale for Users of Bibliometric Indicators , 2015 .

[34]  Adèle Paul-Hus,et al.  The journal coverage of Web of Science and Scopus: a comparative analysis , 2015, Scientometrics.

[35]  A. Janssens,et al.  Novel citation-based search method for scientific literature: application to meta-analyses , 2015, BMC Medical Research Methodology.

[36]  D. Vancampfort,et al.  Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta‐analysis , 2015, World psychiatry : official journal of the World Psychiatric Association.

[37]  O. Howes,et al.  Glutamate and dopamine in schizophrenia: An update for the 21st century , 2015, Journal of psychopharmacology.

[38]  A. Altamura,et al.  Clinical pharmacology of atypical antipsychotics: an update , 2014, EXCLI journal.

[39]  R. Baldessarini,et al.  A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania , 2014, Psychological Medicine.

[40]  C. Spencer,et al.  Biological Insights From 108 Schizophrenia-Associated Genetic Loci , 2014, Nature.

[41]  Dimitris Mavridis,et al.  Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis , 2013, The Lancet.

[42]  T. Perneger,et al.  Citation bias favoring statistically significant studies was present in medical research. , 2013, Journal of clinical epidemiology.

[43]  A. Meyer-Lindenberg,et al.  Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication , 2012, Neuroscience & Biobehavioral Reviews.

[44]  H. Möller,et al.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance , 2012, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[45]  Norbert Schmitz,et al.  Publication bias: what are the challenges and can they be overcome? , 2012, Journal of psychiatry & neuroscience : JPN.

[46]  B. Kirkpatrick,et al.  Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects , 2011, Biological Psychiatry.

[47]  J. Tiihonen,et al.  A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. , 2011, The American journal of psychiatry.

[48]  Kevin W. Boyack,et al.  Co-citation analysis, bibliographic coupling, and direct citation: Which citation approach represents the research front most accurately? , 2010, J. Assoc. Inf. Sci. Technol..

[49]  C. Correll.  From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics , 2010, European Psychiatry.

[50]  John M. Davis,et al.  Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. , 2010, Schizophrenia bulletin.

[51]  Jianhua Hou,et al.  The structure and dynamics of cocitation clusters: A multiple-perspective cocitation analysis , 2010, J. Assoc. Inf. Sci. Technol..

[52]  Ludo Waltman,et al.  Software survey: VOSviewer, a computer program for bibliometric mapping , 2009, Scientometrics.

[53]  Steven A Greenberg,et al.  How citation distortions create unfounded authority: analysis of a citation network , 2009, BMJ : British Medical Journal.

[54]  John M. Davis,et al.  Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis , 2009, The Lancet.

[55]  Yoshiyuki Takeda,et al.  Detecting emerging research fronts based on topological measures in citation networks of scientific publications , 2008 .

[56]  M. Arranz,et al.  Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research , 2007, Molecular Psychiatry.

[57]  Michael F. Green,et al.  Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. , 2007, Archives of general psychiatry.

[58]  L. Egghe,et al.  Theory and practise of the g-index , 2006, Scientometrics.

[59]  Chaomei Chen,et al.  CiteSpace II: Detecting and visualizing emerging trends and transient patterns in scientific literature , 2006, J. Assoc. Inf. Sci. Technol..

[60]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[61]  S. Potkin,et al.  Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. , 2003, Archives of general psychiatry.

[62]  Jon M. Kleinberg,et al.  Bursty and Hierarchical Structure in Streams , 2002, Data Mining and Knowledge Discovery.

[63]  M. Heo,et al.  Antipsychotic-induced weight gain: a comprehensive research synthesis. , 1999, The American journal of psychiatry.

[64]  M. Tohen,et al.  Olanzapine versus placebo in the treatment of acute mania , 1998, European Psychiatry.

[65]  J. Arnt,et al.  Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence , 1998, Neuropsychopharmacology.

[66]  R. Tamura,et al.  Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. , 1997, The American journal of psychiatry.

[67]  J. Gray,et al.  Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET , 1995, Schizophrenia Research.

[68]  S. Marder,et al.  Risperidone in the treatment of schizophrenia. , 1994, The American journal of psychiatry.

[69]  A Labelle,et al.  A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. , 1993, Journal of clinical psychopharmacology.

[70]  D. Goff,et al.  Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. , 1992, The American journal of psychiatry.

[71]  K. Davis,et al.  Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.

[72]  R. McCreadie,et al.  An open multicentre study of the treatment of florid schizophrenia with remoxipride , 1985, Acta psychiatrica Scandinavica.

[73]  A Carlsson,et al.  Antipsychotic drugs, neurotransmitters, and schizophrenia. , 1978, The American journal of psychiatry.

[74]  Leonard M. Freeman,et al.  A set of measures of centrality based upon betweenness , 1977 .

[75]  Henry G. Small,et al.  Co-citation in the scientific literature: A new measure of the relationship between two documents , 1973, J. Am. Soc. Inf. Sci..

[76]  M. Zax,et al.  Reserpine alone and as an adjunct to psychotherapy in the treatment of schizophrenia. , 1955, A M A Archives of Neurology & Psychiatry.

[77]  Martin Fenner,et al.  Altmetrics and Other Novel Measures for Scientific Impact , 2014 .

[78]  Julie Kreyenbuhl,et al.  The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. , 2010, Schizophrenia bulletin.

[79]  Klaus Lindpaintner,et al.  Pharmacogenetics and pharmacogenomics. , 2005, Methods in molecular medicine.

[80]  Nathan Clark.  Consensus development conference on antipsychotic drugs and obesity and diabetes. , 2004, The Journal of clinical psychiatry.

[81]  H. Meltzer,et al.  The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. , 1999, Schizophrenia bulletin.